Evidence that Fgf10 contributes to the skeletal and visceral defects of an apert syndrome mouse model

Developmental Dynamics

Volumn 238, Issue 2, 2009, Pages 376-385

  Hajihosseini, Mohammad K ^a   Duarte, Raquel ^b,f   Pegrum, Jean ^b   Donjacour, Anne ^c   Lana Elola, Eva ^d   Rice, David P ^d,g   Sharpe, James ^e   Dickson, Clive ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Apert syndrome; Craniosynostosis; FGF10; FGFR2 signaling; Lung; Sternum

Indexed keywords

FIBROBLAST GROWTH FACTOR 10;

ACROCEPHALOSYNDACTYLY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLEFT PALATE; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ACROCEPHALOSYNDACTYLIA; ANIMALS; BONE AND BONES; CLEFT PALATE; COLON; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 10; GENE KNOCKDOWN TECHNIQUES; LUNG; MICE; MICE, MUTANT STRAINS; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN ISOFORMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SIGNAL TRANSDUCTION; VISCERA;

MUS;

EID: 59649102280     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.21648     Document Type: Article

References (51)

1. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7:1475-1483.
2. Bellusci S, Grindley J, Emoto H, Itoh N, Hogan BL. 1997. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. Development 124:4867-4878.
3. Bochukova E, Roscioli T, Hedges DJ, Taylor IB, Johnson D, David DJ, Deininger PL, Wilkie AOM. 2008 Rare Mutations of FGFR2 causing Apert syndrome: identification of the first partial gene deletion, and an Alu element insertion from a new family. Human Mutation (in press).
4. Carlton MB, Colledge WH, Evans MJ. 1998. Crouzon-like craniofacial dysmorphology in the mouse is caused by an insertional mutation at the Fgf3/Fgf4 locus. Dev Dyn 212:242-249.
5. Cohen MM Jr, Kreiborg S. 1993a. An updated pediatric perspective on the Apert syndrome. Am J Dis Child 147:989-993.
6. Cohen MM Jr, Kreiborg S. 1993b. Visceral anomalies in the Apert syndrome. Am J Med Genet 45:758-760.
7. De Langhe SP, Carraro G, Warburton D, Hajihosseini MK, Bellusci S. 2006. Levels of mesenchymal FGFR2 signaling modulate smooth muscle progenitor cell commitment in the lung. Dev Biol 299:52-62.
8. De Moerlooze L, Spencer-Dene B, Revest J, Hajihosseini M, Rosewell I, Dickson C. 2000. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 127:483-492.
9. Entesarian M, Matsson H, Klar J, Bergendal B, Olson L, Arakaki R, Hayashi Y, Ohuchi H, Falahat B, Bolstad AI, Jonsson R, Wahren-Herlenius M, Dahl N. 2005. Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands. Nat Genet 37:125-127.
10. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM, Lonai P. 2002. The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development 129:3783-3793.
11. Eswarakumar VP, Ozcan F, Lew ED, Bae JH, Tome F, Booth CJ, Adams DJ, Lax I, Schlessinger J. 2006. Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proc Natl Acad Sci USA 103:18603-18608.
12. Hajihosseini MK. 2008. Fibroblast growth factor signaling in cranial suture development and pathogenesis. Front Oral Biol 12:160-177.
13. Hajihosseini MK, Heath JK. 2002. Expression patterns of fibroblast growth factors-18 and -20 in mouse embryos is suggestive of novel roles in calvarial and limb development. Mech Dev 113:79-83.
14. Hajihosseini MK, Wilson S, De Moerlooze L, Dickson C. 2001. A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes. Proc Natl Acad Sci USA 98:3855-3860.
15. Hajihosseini MK, Lalioti MD, Arthaud S, Burgar HR, Brown JM, Twigg SR, Wilkie AO, Heath JK. 2004. Skeletal development is regulated by fibroblast growth factor receptor 1 signalling dynamics. Development 131:325-335.
16. Hasegawa H, Ashigaki S, Takamatsu M, Suzuki-Migishima R, Ohbayashi N, Itoh N, Takada S, Tanabe Y. 2004. Laminar patterning in the developing neocortex by temporally coordinated fibroblast growth factor signaling. J Neurosci 24:8711-8719.
17. Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM, Mohammadi M. 2001. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci USA 98:7182-7187.
18. Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, Mohammadi M. 2004. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 13:2313-2324.
19. Iseki S, Wilkie AO, Heath JK, Ishimaru T, Eto K, Morriss-Kay GM. 1997. Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. Development 124:3375-3384.
20. Iseki S, Wilkie AO, Morriss-Kay GM. 1999. Fgfr1 and Fgfr2 have distinct differentiation-and proliferation-related roles in the developing mouse skull vault. Development 126:5611-5620.
21. Itoh N, Ornitz DM. 2008. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237:18-27.
22. Jaskoll T, Zhou YM, Chai Y, Makarenkova HP, Collinson JM, West JD, Hajihosseini MK, Lee J, Melnick M. 2002. Embryonic submandibular gland morphogenesis: stage-specific protein localization of FGFs, BMPs, Pax6 and Pax9 in normal mice and abnormal SMG phenotypes in FgfR2-IIIc(+/Delta), BMP7(-/-) and Pax6(-/-) mice. Cells Tissues Organs 170:83-98.
23. Jaskoll T, Abichaker G, Witcher D, Sala FG, Bellusci S, Hajihosseini MK, Melnick M. 2005. FGF10/FGFR2b signaling plays essential roles during in vivo embryonic submandibular salivary gland morphogenesis. BMC Dev Biol 5:11.
24. Lallemand Y, Luria V, Haffner-Krausz R, Lonai P. 1998. Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase. Transgenic Res 7:105-112.
25. Lewandoski M, Sun X, Martin GR. 2000. Fgf8 signalling from the AER is essential for normal limb development. Nat Genet 26:460-463.
26. Liu Z, Xu J, Colvin JS, Ornitz DM. 2002. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev 16:859-869.
27. Mailleux AA, Tefft D, Ndiaye D, Itoh N, Thiery JP, Warburton D, Bellusci S. 2001. Evidence that SPROUTY2 functions as an inhibitor of mouse embryonic lung growth and morphogenesis. Mech Dev 102:81-94.
28. Makarenkova HP, Ito M, Govindarajan V, Faber SC, Sun L, McMahon G, Overbeek PA, Lang RA. 2000. FGF10 is an inducer and Pax6 a competence factor for lacrimal gland development. Development 127:2563-2572.
29. McKeehan WL, Wang F, Kan M. 1998. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol 59:135-176.
30. Milunsky JM, Zhao G, Maher TA, Colby R, Everman DB. 2006. LADD syndrome is caused by FGF10 mutations. Clin Genet 69:349-354.
31. Min H, Danilenko DM, Scully SA, Bolon B, Ring BD, Tarpley JE, DeRose M, Simonet WS. 1998. Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev 12:3156-3161.
32. Motoyama J, Liu J, Mo R, Ding Q, Post M, Hui CC. 1998. Essential function of Gli2 and Gli3 in the formation of lung, trachea and oesophagus. Nat Genet 20:54-57.
33. Ohuchi H, Hori Y, Yamasaki M, Harada H, Sekine K, Kato S, Itoh N. 2000. FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem Biophys Res Commun 277:643-649.
34. Oldridge M, Zackai EH, McDonald-McGinn DM, Iseki S, Morriss-Kay GM, Twigg SR, Johnson D, Wall SA, Jiang W, Theda C, Jabs EW, Wilkie AO. 1999. De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome. Am J Hum Genet 64:446-461.
35. Ornitz DM, Marie PJ. 2002. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16:1446-1465.
36. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D, Lonai P. 1993. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 158:475-486.
37. Partanen J, Schwartz L, Rossant J. 1998. Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos. Genes Dev 12:2332v2344.
38. Passos-Bueno MR, Serti Eacute AE, Jehee FS, Fanganiello R, Yeh E. 2008. Genetics of craniosynostosis: genes, syndromes, mutations and genotype-phenotype correlations. Front Oral Biol 12:107-143.
39. Peters KG, Werner S, Chen G, Williams LT. 1992. Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development 114:233-243.
40. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. 1999. Structural basis for FGF receptor dimerization and activation. Cell 98:641-650.
41. Rice DP, Rice R, Thesleff I. 2003. Fgfr mRNA isoforms in craniofacial bone development. Bone 33:14-27.
42. Sharpe J, Ahlgren U, Perry P, Hill B, Ross A, Hecksher-Sorensen J, Baldock R, Davidson D. 2002. Optical projection tomography as a tool for 3D microscopy and gene expression studies. Science 296:541-545.
43. Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. 2007. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet 39:1145-1150.
44. Slaney SF, Oldridge M, Hurst JA, Moriss-Kay GM, Hall CM, Poole MD, Wilkie AO. 1996. Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. Am J Hum Genet 58:923-932.
45. Stanton LA, Underhill TM, Beier F. 2003. MAP kinases in chondrocyte differentiation. Dev Biol 263:165-175.
46. Tsang M, Dawid IB. 2004. Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. Sci STKE 2004:pe17.
47. Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ, Cai J, Lerner CP, Richtsmeier JT, Leszl JM, Hill CA, Yu K, Ornitz DM, Elisseeff J, Huso DL, Jabs EW. 2005. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2+/S252W mouse. Development 132:3537-3548.
48. Werner S, Weinberg W, Liao X, Peters KG, Blessing M, Yuspa SH, Weiner RL, Williams LT. 1993. Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. Embo J 12:2635-2643.
49. Wilkie AO. 2005. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16:187-203.
50. Yu K, Herr AB, Waksman G, Ornitz DM. 2000. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 97:14536-14541.
51. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. 2006. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281:15694-15700.